Table of Contents

Maintenance rituximab every two months for two years is effective and well tolerated in patients with follicular lymphoma, using standard or rapid infusion: updated results from MAXIMA

NE Oncology Issue - March 2011 Foà R, et al. ASH 2010: Abstract 3945 Background Data from the PRIMA and MAXIMA maintenance trials have added to the growing body of evidence to support induction and maintenance with rituximab as an important strategy for the management...

Download Journal

oncol_issue

Canadian Perspectives

dr-connors
Joseph M. Connors, MD, FRCPC
Dr. Joseph Connors is a clinical professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the Clinical Director of the BC Cancer Agency Centre for Lymphoid Cancer. He is best known for his clinical investigations into the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, chronic lymphocytic leukemias and multiple myeloma. He serves as a member of the executive committee of the Hematology Site Group for the National Cancer Institute of Canada Clinical Trials Group, as chair of the Educational Affairs Committee of the American Society of Hematology, and on the scientific advisory boards of the Lymphoma Foundation Canada and the Lymphoma Research Foundation of the United States. Dr. Connors has published over 250 peer-reviewed scientific articles addressing various aspects of research into lymphoid cancers.

dr-couban
Stephen Couban, MD, FRCPC
Dr. Stephen Couban is a professor of medicine at Dalhousie University and Director of the Blood and Marrow Transplant Program at Capital District Health Authority in Halifax, Nova Scotia. He is Co-Chair of the NCIC CTG Hematology Site Group and is also active with the Canadian Blood and Marrow Transplant Group. Dr. Couban is Vice President of the Canadian Hematology Society and a past-president of the Canadian Blood and Marrow Transplant Group. His research interests have focused on allografting and in particular on exploration of different types of grafts, including GCSF-stimulated allogeneic peripheral blood allografts and GCSF-stimulated bone marrow allografts. He is actively involved in a number of clinical trials for patients with leukemia and lymphoma, as well as those undergoing blood and marrow transplantation.

dr-stewart
Douglas A. Stewart, BMSc, MD, FRCPC
Dr. Douglas A. Stewart is currently a professor in the Departments of Oncology and Medicine, and Chief of the Division of Hematology and Hematological Malignancies at the University of Calgary. Since July 1994, he has been practising medical oncology at the Tom Baker Cancer Centre in Calgary, where he is a member of the Breast Cancer and Hematology Tumour Groups, Leader of the Hematology/Blood and Marrow Transplant Program, and Provincial Leader of the Hematology Tumour Team for the Alberta Health Services Cancer Care Program. His research interests focus on clinical trials involving hematological malignancies and hematopoietic stem cell transplantation. Dr. Stewart has authored over 80 peer-reviewed manuscripts and over 120 abstracts.

Investigator Commentary

dr-stewart
Kirit Ardeshna, MD
Dr. Kirit Ardeshna is a consultant hematologist at University College London Hospital NHS Trust in London, UK, where he is lead clinician for the clinical hematology service. He also works at the Mount Vernon Cancer Center in Northwood, UK. Dr. Ardeshna specializes in managing patients with hematological malignancies and has a particular interest in treating patients with lymphoma. His research interest is in clinical trials in lymphoma, and he has been a member of the National Cancer Research Institute Lymphoma Studies Group since 2005. A Fellow of the Royal College of Physicians and Royal College of Pathologists in the United Kingdom and a member of The British Committee for Standards in Haematology, Dr. Ardeshna is the Chief Investigator of an intergroup randomized trial comparing rituximab treatment with a watch and wait strategy in asymptomatic, non-bulky follicular lymphoma.